Search
Eledon Pharmaceuticals Inc
ELDNAdd to Watchlist
3.800USD
-0.150-3.80%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
293.31MMarket Cap
LossP/E TTM
More Details of Eledon Pharmaceuticals Inc Company
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Eledon Pharmaceuticals Inc Info
Ticker SymbolELDN
Company nameEledon Pharmaceuticals Inc
IPO dateSep 17, 2014
CEOGros (David-Alexandre C)
Number of employees31
Security typeOrdinary Share
Fiscal year-endSep 17
Address19800 Macarthur Blvd.
CityIRVINE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92612
Phone19492388090
Websitehttps://eledon.com/
Ticker SymbolELDN
IPO dateSep 17, 2014
CEOGros (David-Alexandre C)
Company Executives of Eledon Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David-Alexandre C. (DA) Gros, M.D.
Dr. David-Alexandre C. (DA) Gros, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
9.00K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
677.00
-1266.62%
Mr. John S. McBride
Mr. John S. McBride
Independent Director
Independent Director
--
-100.00%
Dr. Steven N. Perrin, Ph.D.
Dr. Steven N. Perrin, Ph.D.
President, Chief Scientific Officer, Director
President, Chief Scientific Officer, Director
--
--
Dr. June Lee, M.D.
Dr. June Lee, M.D.
Independent Director
Independent Director
--
--
Mr. Paul Little
Mr. Paul Little
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Bryan E. Smith, J.D.
Mr. Bryan E. Smith, J.D.
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Jan Hillson, M.D.
Dr. Jan Hillson, M.D.
Independent Director
Independent Director
--
--
Mr. James Robinson
Mr. James Robinson
Independent Director
Independent Director
--
--
Dr. Allan D. Kirk, M.D., Ph.D.
Dr. Allan D. Kirk, M.D., Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. David-Alexandre C. (DA) Gros, M.D.
Dr. David-Alexandre C. (DA) Gros, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
9.00K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
677.00
-1266.62%
Mr. John S. McBride
Mr. John S. McBride
Independent Director
Independent Director
--
-100.00%
Dr. Steven N. Perrin, Ph.D.
Dr. Steven N. Perrin, Ph.D.
President, Chief Scientific Officer, Director
President, Chief Scientific Officer, Director
--
--
Dr. June Lee, M.D.
Dr. June Lee, M.D.
Independent Director
Independent Director
--
--
Mr. Paul Little
Mr. Paul Little
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BVF Partners L.P.
8.15%
BlackRock Institutional Trust Company, N.A.
4.28%
Vanguard Capital Management, LLC
4.27%
Defilade Capital Management, L.P.
4.26%
Ensign Peak Advisors, Inc.
3.19%
Other
75.85%
Shareholders
Shareholders
Proportion
BVF Partners L.P.
8.15%
BlackRock Institutional Trust Company, N.A.
4.28%
Vanguard Capital Management, LLC
4.27%
Defilade Capital Management, L.P.
4.26%
Ensign Peak Advisors, Inc.
3.19%
Other
75.85%
Shareholder Types
Shareholders
Proportion
Hedge Fund
23.74%
Investment Advisor
19.50%
Investment Advisor/Hedge Fund
8.50%
Research Firm
3.42%
Venture Capital
1.79%
Corporation
1.06%
Bank and Trust
0.11%
Pension Fund
0.05%
Insurance Company
0.03%
Other
41.82%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
219
43.90M
56.87%
-12.12M
2025Q4
174
40.57M
62.44%
+4.76M
2025Q3
174
35.81M
78.25%
-4.68M
2025Q2
155
40.45M
72.00%
+2.71M
2025Q1
116
37.67M
69.38%
-3.87M
2024Q4
99
37.64M
45.44%
+12.04M
2024Q3
63
18.54M
49.04%
+220.67K
2024Q2
64
18.69M
36.55%
+6.56M
2024Q1
59
10.03M
46.51%
-1.52M
2023Q4
57
9.58M
48.06%
+248.88K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BVF Partners L.P.
6.29M
8.3%
--
--
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
3.30M
4.35%
+168.79K
+5.39%
Dec 31, 2025
Defilade Capital Management, L.P.
3.29M
4.34%
+3.29M
--
Dec 31, 2025
Ensign Peak Advisors, Inc.
2.46M
3.25%
+1.20M
+94.87%
Dec 31, 2025
Zimmer Partners, LP
2.38M
3.14%
+559.23K
+30.64%
Dec 31, 2025
Sphera Funds Management Ltd.
2.13M
2.81%
+851.90K
+66.54%
Dec 31, 2025
Blue Owl Capital Holdings LP
1.93M
2.54%
+950.00K
+96.95%
Dec 31, 2025
Adar1 Capital Management LLC
1.82M
2.4%
+1.82M
--
Dec 31, 2025
Geode Capital Management, L.L.C.
1.42M
1.87%
+52.68K
+3.85%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.05%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Avantis US Small Cap Equity ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
ALPS Medical Breakthroughs ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.05%
Global X Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
ALPS Medical Breakthroughs ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
Date
Ex-dividend Date
Type
Ratio
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
